Example of Current Gene Therapy format
Recent searches

Example of Current Gene Therapy format Example of Current Gene Therapy format Example of Current Gene Therapy format Example of Current Gene Therapy format
Sample paper formatted on SciSpace - SciSpace
This content is only for preview purposes. The original open access content can be found here.
Look Inside
Example of Current Gene Therapy format Example of Current Gene Therapy format Example of Current Gene Therapy format Example of Current Gene Therapy format
Sample paper formatted on SciSpace - SciSpace
This content is only for preview purposes. The original open access content can be found here.
open access Open Access

Current Gene Therapy — Template for authors

Publisher: Bentham Science
Categories Rank Trend in last 3 yrs
Genetics #139 of 325 down down by 8 ranks
Genetics (clinical) #38 of 87 down down by 1 rank
Drug Discovery #64 of 145 down down by 13 ranks
Molecular Biology #218 of 382 down down by 34 ranks
Molecular Medicine #97 of 167 down down by 17 ranks
journal-quality-icon Journal quality:
Good
calendar-icon Last 4 years overview: 144 Published Papers | 675 Citations
indexed-in-icon Indexed in: Scopus
last-updated-icon Last updated: 27/06/2020
Related journals
Insights
General info
Top papers
Popular templates
Get started guide
Why choose from SciSpace
FAQ

Related Journals

open access Open Access
recommended Recommended

Springer

Quality:  
High
CiteRatio: 15.2
SJR: 5.564
SNIP: 2.245
open access Open Access

Springer

Quality:  
Good
CiteRatio: 5.3
SJR: 1.414
SNIP: 1.018
open access Open Access
recommended Recommended

PLOS

Quality:  
High
CiteRatio: 9.0
SJR: 3.587
SNIP: 1.457
open access Open Access

Springer

Quality:  
Good
CiteRatio: 4.6
SJR: 1.028
SNIP: 1.006

Journal Performance & Insights

Impact Factor

CiteRatio

Determines the importance of a journal by taking a measure of frequency with which the average article in a journal has been cited in a particular year.

A measure of average citations received per peer-reviewed paper published in the journal.

2.431

10% from 2018

Impact factor for Current Gene Therapy from 2016 - 2019
Year Value
2019 2.431
2018 2.218
2017 1.943
2016 2.78
graph view Graph view
table view Table view

4.7

24% from 2019

CiteRatio for Current Gene Therapy from 2016 - 2020
Year Value
2020 4.7
2019 3.8
2018 4.5
2017 4.6
2016 5.2
graph view Graph view
table view Table view

insights Insights

  • Impact factor of this journal has increased by 10% in last year.
  • This journal’s impact factor is in the top 10 percentile category.

insights Insights

  • CiteRatio of this journal has increased by 24% in last years.
  • This journal’s CiteRatio is in the top 10 percentile category.

SCImago Journal Rank (SJR)

Source Normalized Impact per Paper (SNIP)

Measures weighted citations received by the journal. Citation weighting depends on the categories and prestige of the citing journal.

Measures actual citations received relative to citations expected for the journal's category.

0.704

10% from 2019

SJR for Current Gene Therapy from 2016 - 2020
Year Value
2020 0.704
2019 0.782
2018 1.008
2017 0.951
2016 1.323
graph view Graph view
table view Table view

0.589

24% from 2019

SNIP for Current Gene Therapy from 2016 - 2020
Year Value
2020 0.589
2019 0.475
2018 0.567
2017 0.515
2016 0.762
graph view Graph view
table view Table view

insights Insights

  • SJR of this journal has decreased by 10% in last years.
  • This journal’s SJR is in the top 10 percentile category.

insights Insights

  • SNIP of this journal has increased by 24% in last years.
  • This journal’s SNIP is in the top 10 percentile category.

Current Gene Therapy

Guideline source: View

All company, product and service names used in this website are for identification purposes only. All product names, trademarks and registered trademarks are property of their respective owners.

Use of these names, trademarks and brands does not imply endorsement or affiliation. Disclaimer Notice

Bentham Science

Current Gene Therapy

Current Gene Therapy is an interdisciplinary journal focused on providing the readership with current and comprehensive review articles, original research articles, letters/ short communications and guest edited issues on all aspects of gene therapy. The journal is aimed at al...... Read More

Drug Discovery

Genetics

Genetics(clinical)

Molecular Medicine

Molecular Biology

Pharmacology, Toxicology and Pharmaceutics

i
Last updated on
27 Jun 2020
i
ISSN
1566-5232
i
Impact Factor
High - 1.283
i
Open Access
Yes
i
Sherpa RoMEO Archiving Policy
Yellow faq
i
Plagiarism Check
Available via Turnitin
i
Endnote Style
Download Available
i
Bibliography Name
Vancouver
i
Citation Type
Numbered
[25]
i
Bibliography Example
Blonder, G E, Tinkham, M, & Klapwijk, T M. Transition from metallic to tunnel- ing regimes in superconducting microconstrictions: Excess current, charge imbalance, and supercurrent conversion. Phys. Rev. B. 2013;87(10):100510.

Top papers written in this journal

open accessOpen access Journal Article DOI: 10.2174/1566523054546224
Altering the tropism of lentiviral vectors through pseudotyping.
James Cronin1, Xian Yang Zhang, Jakob Reiser
31 Jul 2005 - Current Gene Therapy

Abstract:

The host range of retroviral vectors including lentiviral vectors can be expanded or altered by a process known as pseudotyping Pseudotyped lentiviral vectors consist of vector particles bearing glycoproteins (GPs) derived from other enveloped viruses Such particles possess the tropism of the virus from which the GP was deriv... The host range of retroviral vectors including lentiviral vectors can be expanded or altered by a process known as pseudotyping Pseudotyped lentiviral vectors consist of vector particles bearing glycoproteins (GPs) derived from other enveloped viruses Such particles possess the tropism of the virus from which the GP was derived For example, to exploit the natural neural tropism of rabies virus, vectors designed to target the central nervous system have been pseudotyped using rabies virus-derived GPs Among the first and still most widely used GPs for pseudotyping lentiviral vectors is the vesicular stomatitis virus GP (VSV-G), due to the very broad tropism and stability of the resulting pseudotypes Pseudotypes involving VSV-G have become effectively the standard for evaluating the efficiency of other pseudotypes This review samples a few of the more prominent examples from the ever-expanding list of published lentiviral pseudotypes, noting comparisons made with pseudotypes involving VSV-G in terms of titer, viral particle stability, toxicity, and host-cell specificity Particular attention is paid to publications of successfully targeting a specific organ or cell types read more read less

Topics:

Pseudotyping (68%)68% related to the paper, Tropism (54%)54% related to the paper, Vesicular stomatitis virus (52%)52% related to the paper
498 Citations
Journal Article DOI: 10.2174/1566523054065057
New recombinant serotypes of AAV vectors.
Guangping Gao1, Luk H. Vandenberghe, James M. Wilson
31 May 2005 - Current Gene Therapy

Abstract:

AAV based vectors can achieve stable gene transfer with minimal vector related toxicities. AAV serotype 2 (AAV2) is the first AAV that was vectored for gene transfer applications. However, the restricted tissue tropism of AAV and its low transduction efficiency have limited its further development as vector. Recent studies us... AAV based vectors can achieve stable gene transfer with minimal vector related toxicities. AAV serotype 2 (AAV2) is the first AAV that was vectored for gene transfer applications. However, the restricted tissue tropism of AAV and its low transduction efficiency have limited its further development as vector. Recent studies using vectors derived from alternative AAV serotypes such as AAV1, 4, 5 and 6 have shown improved potency and broadened tropism of the AAV vector by packaging the same vector genome with different AAV capsids. In an attempt to search for potent AAV vectors with enhanced performance profiles, molecular techniques were employed for the detection and isolation of endogenous AAVs from a variety of human and non-human primate (NHP) tissues. A family of novel primate AAVs consisting of 110 non-redundant species of proviral sequences was discovered and turned to be prevalent in 18-19% of the tissues evaluated. Phylogenetic and functional analyses revealed that primate AAVs are segregated into clades based on phylogenetic relatedness. The members within a clade share functional and serological properties. Initial evaluation in mouse models of vectors based on these novel AAVs for tissue tropism and gene transfer potency led to the identification of some vector with improved gene transfer to different target tissues. Gene therapy treatment of several mouse and canine models with novel AAV vectors achieved long term phenotypic corrections. Vectors based on new primate AAVs could become the next generation of efficient gene transfer vehicles for various gene therapy applications. read more read less

Topics:

Genetic transfer (53%)53% related to the paper, Tissue tropism (51%)51% related to the paper
490 Citations
open accessOpen access Journal Article DOI: 10.2174/1566523213666131125095046
Adenovirus Vectors for Gene Therapy, Vaccination and Cancer Gene Therapy
William S. M. Wold, Karoly Toth1
31 Jan 2014 - Current Gene Therapy

Abstract:

Adenovirus vectors are the most commonly employed vector for cancer gene therapy. They are also used for gene therapy and as vaccines to express foreign antigens. Adenovirus vectors can be replication-defective; certain essential viral genes are deleted and replaced by a cassette that expresses a foreign therapeutic gene. Suc... Adenovirus vectors are the most commonly employed vector for cancer gene therapy. They are also used for gene therapy and as vaccines to express foreign antigens. Adenovirus vectors can be replication-defective; certain essential viral genes are deleted and replaced by a cassette that expresses a foreign therapeutic gene. Such vectors are used for gene therapy, as vaccines, and for cancer therapy. Replication-competent (oncolytic) vectors are employed for cancer gene therapy. Oncolytic vectors are engineered to replicate preferentially in cancer cells and to destroy cancer cells through the natural process of lytic virus replication. Many clinical trials indicate that replication-defective and replication-competent adenovirus vectors are safe and have therapeutic activity. read more read less

Topics:

Oncolytic virus (62%)62% related to the paper, Vector (molecular biology) (61%)61% related to the paper, Adenoviridae (55%)55% related to the paper, Genetic enhancement (54%)54% related to the paper
394 Citations
open accessOpen access Journal Article DOI: 10.2174/156652311794520111
Meganucleases and other tools for targeted genome engineering: perspectives and challenges for gene therapy.
31 Jan 2011 - Current Gene Therapy

Abstract:

The importance of safer approaches for gene therapy has been underscored by a series of severe adverse events (SAEs) observed in patients involved in clinical trials for Severe Combined Immune Deficiency Disease (SCID) and Chromic Granulomatous Disease (CGD). While a new generation of viral vectors is in the process of replac... The importance of safer approaches for gene therapy has been underscored by a series of severe adverse events (SAEs) observed in patients involved in clinical trials for Severe Combined Immune Deficiency Disease (SCID) and Chromic Granulomatous Disease (CGD). While a new generation of viral vectors is in the process of replacing the classical gamma-retrovirus – based approach, a number of strategies have emerged based on non-viral vectorization and/or targeted insertion aimed at achieving safer gene transfer. Currently, these methods display lower efficacies than viral transduction although many of them can yield more than 1% engineered cells in vitro. Nuclease-based approaches, wherein an endonuclease is used to trigger site-specific genome editing, can significantly increase the percentage of targeted cells. These methods therefore provide a real alternative to classical gene transfer as well as gene editing. However, the first endonuclease to be in clinic today is not used for gene transfer, but to inactivate a gene (CCR5) required for HIV infection. Here, we review these alternative approaches, with a special emphasis on meganucleases, a family of naturally occurring rare-cutting endonucleases, and speculate on their current and future potential. read more read less

Topics:

Genome engineering (57%)57% related to the paper, Genome editing (57%)57% related to the paper, Meganuclease (55%)55% related to the paper, Genetic transfer (54%)54% related to the paper, Viral vector (52%)52% related to the paper
View PDF
372 Citations
Journal Article DOI: 10.2174/156652307779940216
Meganucleases and DNA double-strand break-induced recombination : Perspectives for gene therapy
31 Jan 2007 - Current Gene Therapy

Abstract:

Meganucleases are sequence-specific endonucleases recognizing large (>12 bp) sequence sites and several laboratories have used these proteins to induce highly efficient gene targeting in mammalian cells. The recent development of artificial endonucleases with tailored specificities has opened the door for a wide range of new ... Meganucleases are sequence-specific endonucleases recognizing large (>12 bp) sequence sites and several laboratories have used these proteins to induce highly efficient gene targeting in mammalian cells. The recent development of artificial endonucleases with tailored specificities has opened the door for a wide range of new applications, including therapeutic ones: redesigned endonucleases cleaving chosen sequences could be used to in gene therapy to correct mutated genes or introduce transgenes in chosen loci. Such "targeted" approaches markedly differ from current gene therapy strategies based on the random insertion of a complementing virus-borne transgene. As a consequence, they should bypass the odds of random insertion. Artificial fusion proteins including Zinc-Finger binding domains have provided important proofs of concept, however the toxicity of these proteins is still an issue. Today custom-designed homing endonucleases, the natural meganucleases, could represent an efficient alternative. After a brief description of the origin of the technology, current systems based on redesigned endonucleases will be presented, with a special emphasis on the recent advances in homing endonuclease engineering. Finally, we will discuss the main issues that will need to be addressed in order to bring this promising technology to the patient. read more read less

Topics:

Homing endonuclease (61%)61% related to the paper, Meganuclease (58%)58% related to the paper, Genome engineering (57%)57% related to the paper, Gene targeting (53%)53% related to the paper
348 Citations
Author Pic

SciSpace is a very innovative solution to the formatting problem and existing providers, such as Mendeley or Word did not really evolve in recent years.

- Andreas Frutiger, Researcher, ETH Zurich, Institute for Biomedical Engineering

Get MS-Word and LaTeX output to any Journal within seconds
1
Choose a template
Select a template from a library of 40,000+ templates
2
Import a MS-Word file or start fresh
It takes only few seconds to import
3
View and edit your final output
SciSpace will automatically format your output to meet journal guidelines
4
Submit directly or Download
Submit to journal directly or Download in PDF, MS Word or LaTeX

(Before submission check for plagiarism via Turnitin)

clock Less than 3 minutes

What to expect from SciSpace?

Speed and accuracy over MS Word

''

With SciSpace, you do not need a word template for Current Gene Therapy.

It automatically formats your research paper to Bentham Science formatting guidelines and citation style.

You can download a submission ready research paper in pdf, LaTeX and docx formats.

Time comparison

Time taken to format a paper and Compliance with guidelines

Plagiarism Reports via Turnitin

SciSpace has partnered with Turnitin, the leading provider of Plagiarism Check software.

Using this service, researchers can compare submissions against more than 170 million scholarly articles, a database of 70+ billion current and archived web pages. How Turnitin Integration works?

Turnitin Stats
Publisher Logos

Freedom from formatting guidelines

One editor, 100K journal formats – world's largest collection of journal templates

With such a huge verified library, what you need is already there.

publisher-logos

Easy support from all your favorite tools

Current Gene Therapy format uses Vancouver citation style.

Automatically format and order your citations and bibliography in a click.

SciSpace allows imports from all reference managers like Mendeley, Zotero, Endnote, Google Scholar etc.

Frequently asked questions

1. Can I write Current Gene Therapy in LaTeX?

Absolutely not! Our tool has been designed to help you focus on writing. You can write your entire paper as per the Current Gene Therapy guidelines and auto format it.

2. Do you follow the Current Gene Therapy guidelines?

Yes, the template is compliant with the Current Gene Therapy guidelines. Our experts at SciSpace ensure that. If there are any changes to the journal's guidelines, we'll change our algorithm accordingly.

3. Can I cite my article in multiple styles in Current Gene Therapy?

Of course! We support all the top citation styles, such as APA style, MLA style, Vancouver style, Harvard style, and Chicago style. For example, when you write your paper and hit autoformat, our system will automatically update your article as per the Current Gene Therapy citation style.

4. Can I use the Current Gene Therapy templates for free?

Sign up for our free trial, and you'll be able to use all our features for seven days. You'll see how helpful they are and how inexpensive they are compared to other options, Especially for Current Gene Therapy.

5. Can I use a manuscript in Current Gene Therapy that I have written in MS Word?

Yes. You can choose the right template, copy-paste the contents from the word document, and click on auto-format. Once you're done, you'll have a publish-ready paper Current Gene Therapy that you can download at the end.

6. How long does it usually take you to format my papers in Current Gene Therapy?

It only takes a matter of seconds to edit your manuscript. Besides that, our intuitive editor saves you from writing and formatting it in Current Gene Therapy.

7. Where can I find the template for the Current Gene Therapy?

It is possible to find the Word template for any journal on Google. However, why use a template when you can write your entire manuscript on SciSpace , auto format it as per Current Gene Therapy's guidelines and download the same in Word, PDF and LaTeX formats? Give us a try!.

8. Can I reformat my paper to fit the Current Gene Therapy's guidelines?

Of course! You can do this using our intuitive editor. It's very easy. If you need help, our support team is always ready to assist you.

9. Current Gene Therapy an online tool or is there a desktop version?

SciSpace's Current Gene Therapy is currently available as an online tool. We're developing a desktop version, too. You can request (or upvote) any features that you think would be helpful for you and other researchers in the "feature request" section of your account once you've signed up with us.

10. I cannot find my template in your gallery. Can you create it for me like Current Gene Therapy?

Sure. You can request any template and we'll have it setup within a few days. You can find the request box in Journal Gallery on the right side bar under the heading, "Couldn't find the format you were looking for like Current Gene Therapy?”

11. What is the output that I would get after using Current Gene Therapy?

After writing your paper autoformatting in Current Gene Therapy, you can download it in multiple formats, viz., PDF, Docx, and LaTeX.

12. Is Current Gene Therapy's impact factor high enough that I should try publishing my article there?

To be honest, the answer is no. The impact factor is one of the many elements that determine the quality of a journal. Few of these factors include review board, rejection rates, frequency of inclusion in indexes, and Eigenfactor. You need to assess all these factors before you make your final call.

13. What is Sherpa RoMEO Archiving Policy for Current Gene Therapy?

SHERPA/RoMEO Database

We extracted this data from Sherpa Romeo to help researchers understand the access level of this journal in accordance with the Sherpa Romeo Archiving Policy for Current Gene Therapy. The table below indicates the level of access a journal has as per Sherpa Romeo's archiving policy.

RoMEO Colour Archiving policy
Green Can archive pre-print and post-print or publisher's version/PDF
Blue Can archive post-print (ie final draft post-refereeing) or publisher's version/PDF
Yellow Can archive pre-print (ie pre-refereeing)
White Archiving not formally supported
FYI:
  1. Pre-prints as being the version of the paper before peer review and
  2. Post-prints as being the version of the paper after peer-review, with revisions having been made.

14. What are the most common citation types In Current Gene Therapy?

The 5 most common citation types in order of usage for Current Gene Therapy are:.

S. No. Citation Style Type
1. Author Year
2. Numbered
3. Numbered (Superscripted)
4. Author Year (Cited Pages)
5. Footnote

15. How do I submit my article to the Current Gene Therapy?

It is possible to find the Word template for any journal on Google. However, why use a template when you can write your entire manuscript on SciSpace , auto format it as per Current Gene Therapy's guidelines and download the same in Word, PDF and LaTeX formats? Give us a try!.

16. Can I download Current Gene Therapy in Endnote format?

Yes, SciSpace provides this functionality. After signing up, you would need to import your existing references from Word or Bib file to SciSpace. Then SciSpace would allow you to download your references in Current Gene Therapy Endnote style according to Elsevier guidelines.

Fast and reliable,
built for complaince.

Instant formatting to 100% publisher guidelines on - SciSpace.

Available only on desktops 🖥

No word template required

Typset automatically formats your research paper to Current Gene Therapy formatting guidelines and citation style.

Verifed journal formats

One editor, 100K journal formats.
With the largest collection of verified journal formats, what you need is already there.

Trusted by academicians

I spent hours with MS word for reformatting. It was frustrating - plain and simple. With SciSpace, I can draft my manuscripts and once it is finished I can just submit. In case, I have to submit to another journal it is really just a button click instead of an afternoon of reformatting.

Andreas Frutiger
Researcher & Ex MS Word user
Use this template